2023 Approvals
APHEXDA: A New Frontier in Multiple Myeloma Treatment Approved by the FDA on September 8, 2023
What is APHEXDA prescribed for? APHEXDA is used in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. What is the name of the drug and what does it do? APHEXDA , pronounced ah fex’ dah,